This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Apricus Biosciences To Present Review Of Commercialization Plans For Vitaros(R) And Development Of Product Pipeline At BioPartnering North America Conference(TM)

SAN DIEGO, Calif., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), ( ) today announced that Linda Smibert, Vice President, Business Development at the Company's NexMed, USA, Inc. ("NexMed, USA") subsidiary, will present at the BioPartnering North America Conference in Vancouver, Canada, on Tuesday, March 1, 2011, at 10:15 am PST. The presentation will include an overview of the Company's commercialization plans for Vitaros ®, its first approved product, as well as development of the Company's 12 other products and compounds utilizing its proprietary NexACT ® technology. 

On November 12, 2010, Apricus Bio announced that Health Canada had approved Vitaros ® for marketing as the first topical treatment for ED in that country. The Company announced on December 22, 2010 a licensing agreement with Bracco SpA for the commercialization of Vitaros ® in Italy, and on January 4, 2011, announced the signing of a licensing agreement with Elis Pharmaceuticals for the Gulf Countries and certain countries in the Middle East. Apricus Bio is currently in proactive discussions to expand the commercialization of Vitaros ® to certain other international markets.

Commenting on the upcoming presentation, Dr. Bassam Damaj, President and Chief Executive Officer of the Company, noted, "We are very excited to have this opportunity to present a review of our commercialization progress for Vitaros ® at such a key industry event. Our business development group at NexMed USA has been very proactive in seeking appropriate licensing and commercialization partners throughout the world in order to potentially make this promising drug available to patients in many different countries. In addition to this review, Ms. Smibert will be presenting an update on our 12 other products and compounds in development, including later stage products, such as MycoVa for onychomycosis (nail fungus), PrevOnco for liver cancer, Femprox ® for female sexual arousal disorder, and RayVa for Raynauld's Syndrome, as well as our pre-clinical products in development, in the areas of sexual dysfunction, oncology, autoimmune disease, anti-inflammatory, pain, anti-infectives, diabetes and cosmeceuticals. We are enthusiastic about the opportunity to discuss these products, as well as the underlying NexACT ® technology, and how it may help other companies achieve better results from their own compounds and products."

About Apricus Biosciences, Inc.

Apricus Bio, a San Diego based revenue-generating pharmaceutical company,  has leveraged the flexibility of its clinically-validated NexACT ® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide, as well as monetizing its existing product pipeline, including its approved drug, Vitaros ®, for treatment of erectile dysfunction, in addition to compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals, among others.  For further information on Apricus Bio and its subsidiaries, visit

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, timing for seeking foreign approvals for Vitaros ®, timing and success of the commercial launch of Vitaros ® in Italy, The Gulf Countries and part of the Middle East and in Israel and the Palestinian Territories, the potential size of the markets in each of these countries, the ability to develop and commercialize the Company's products on its own and with partners and the ability to meet its milestones. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
CONTACT:  Apricus Biosciences, Inc.
          Edward Cox
          VP, Investor Relations & Corporate Development
          (858) 848-4249

          Apricus Bio Investor Relations
          Paula Schwartz
          Rx Communications Group, LLC
          (917) 322-2216

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 -1.15%
FB $117.58 0.73%
GOOG $693.01 0.29%
TSLA $240.76 -2.81%
YHOO $36.60 0.03%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs